ARCHIVES

Group Chairmen Object To “Directive” Language In Proposed Intergroup Study Guidelines

This article is from The Cancer Letter archive.

Vol. 10 No. 02 | January 13, 1984

Download PDF Visit The Full Archive

Related Articles

FDA Allows Firms To Distribute Reprints On Unapproved Uses of Products

January 16, 2009

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

July 31, 2009

DCT Programs Status Reported to Board

July 5, 1985

DeVita’s “Radical” Statement – Resectability Rate Should Be The Cure Rate

October 1, 1976

NCI Seeks Nominations For Consumer Liaison Group.

November 23, 2001

NCAB Study Core Guideline Revisions; Final Decision To Await New Division BSC

May 23, 1980